INTERACTION OF INTRAVENOUS DILTIAZEM WITH LOVASTATIN

这项研究将评估是否有一种常用的钙拮抗剂， 即地尔硫卓，已知其具有阻断细胞色素 P450 3A4，并且在之前的研究中已经显示出导致 当口服给药时，与洛伐他汀的药物相互作用将产生相同的 通过胃肠外途径给药时的相互作用。方案将评估 洛伐他汀是否易受药代动力学相互作用的影响， 当给予地尔硫卓时影响活性部分的形成 静脉注射 研究的具体目的是确定观察到的 地尔硫卓与洛伐他汀的相互作用发生在肠水平 或肝脏中。静脉注射地尔硫卓治疗将有助于回答这个问题 通过绕过肠道细胞色素P450 3A4的问题。

This study will assess whether or not a commonly used calcium antagonist, namely diltiazem, that is known to have the capacity to block cytochrome P450 3A4, and which has been shown in out previous study to result in a drug interaction with lovastatin when given orally will produce the same interaction when given by the parenteral route. The protocol will evaluate whether lovastatin is susceptible to pharmacokinetic interactions that effect the formation of active moieties when diltiazem is given intravenously. The specific aims of the study are to determine whether the observed interaction of diltiazem with lovastatin, occurs at the interstinal level or in the liver. Intravenous therapy with diltiazem will help answer this question by bypassing the intestinal cytochrome P450 3A4.